...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient choice as a driver of medication-switching in non-adherent individuals with bipolar disorder
【24h】

Patient choice as a driver of medication-switching in non-adherent individuals with bipolar disorder

机译：患者选择作为具有双相障碍的非粘附性质的药物切换的驾驶员

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Psychotropic-related weight gain is a common concern among patients with bipolar disorder (BD). This concern affects satisfaction with treatment and may lead to non-adherence and relapse. This was a 12-week, uncontrolled prospective trial of patient-choice–facilitated ziprasidone switching among non-adherent BD patients with weight concerns. This study was conducted from January 2011 to July 2012.Method: Patients were asked to identify the “offending” BD medication which they believed was causing weight problems, and this agent was replaced with ziprasidone. The primary outcome was change in adherence as measured with the Tablets Routine Questionnaire (TRQ). Secondary outcomes included medication attitudes, BD symptoms, global psychopathology, social functioning, and quality of life.Results: The most common agents causing weight concerns were quetiapine (N=7, 23%), aripiprazole (N=4, 13%), olanzapine, lithium, and divalproex (all N=3, 10%). Adherence improved from a baseline of missing 48.6% of prescribed BD medication in the past week (44.9% in the past month) to missing 25.3% (P=0.002) of prescribed BD medication in the past week (P<0.001, in the past month) at endpoint. Medication attitudes, symptoms, functioning, and quality of life improved but there were no differences in body weight.Conclusion: While findings must be tempered by methodological limitations such as small sample and uncontrolled design, patient-facilitated medication-switching appeared to improve adherence and BD outcomes in these non-adherent individuals. Additional studies involving patient-facilitated medication-switching and shared decision-making in BD are needed.
机译：目的：精神相关的体重增加是双相障碍（BD）患者的共同关心。这种担忧对治疗的满意感影响，可能导致非依从性和复发。这是一个12周，不受控制的患者选择促进的Ziprasidone在重量关注的非粘附性BD患者之间切换的不受控制的前瞻性试验。本研究于2011年1月至2012年7月进行。方法：患者被要求确定他们认为造成体重问题的“冒犯”的BD药物，并且该试剂用齐普拉西酮取代。通过用片剂常规问卷（TRQ）测量，主要结果是依从性的变化。二次结果包括药物态度，BD症状，全球精神病理学，社会功能和生活质量。结果：导致重量问题的最常见的药剂是喹硫唑（n = 7,33％），阿里希哌唑（n = 4,13％）， Olanzapine，锂和Divallox（所有n = 3,10％）。过去一周缺少48.6％的缺失48.6％的基线（过去一个月44.9％）的基准改善，过去一周缺少25.3％（p = 0.002）规定的BD药物（过去的P <0.001）月份）在端点。治疗态度，症状，运作和生活质量改善，但体重没有差异。结论：虽然表现必须通过诸如小样品和不受控制的设计的方法局限性，患者便利的药物切换似乎改善了依从性和在这些非依赖性的人中的BD结果。需要涉及患者便利的药物切换和BD共享决策的额外研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号